Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes α-synuclein inclusions

被引:99
作者
Sawada, H
Kohno, R
Kihara, T
Izumi, Y
Sakka, N
Ibi, M
Nakanishi, M
Nakamizo, T
Yamakawa, K
Shibasaki, H
Yamamoto, N
Akaike, A
Inden, M
Kitamura, Y
Taniguchi, T
Shimohama, S
机构
[1] Grad Sch Med, Dept Neurol, Sakyo Ku, Kyoto 6068507, Japan
[2] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan
[3] Kyoto Pharmaceut Univ, Dept Neurobiol, Yamashina Ku, Kyoto 6078412, Japan
关键词
D O I
10.1074/jbc.M308434200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Parkinson's disease is characterized by dopaminergic neuronal death and the presence of Lewy bodies. alpha-Synuclein is a major component of Lewy bodies, but the process of its accumulation and its relationship to dopaminergic neuronal death has not been resolved. Although the pathogenesis has not been clarified, mitochondrial complex I is suppressed, and caspase-3 is activated in the affected midbrain. Here we report that a combination of 1-methyl-4-phenylpyridinium ion (MPP+) or rotenone and proteasome inhibition causes the appearance of alpha-synuclein-positive inclusion bodies. Unexpectedly, however, proteasome inhibition blocked MPP+- or rotenone-induced dopaminergic neuronal death. MPP+ elevated proteasome activity, dephosphorylated mitogen-activating protein kinase ( MAPK), and activated caspase-3. Proteasome inhibition reversed the MAPK dephosphorylation and blocked caspase-3 activation; the neuroprotection was blocked by a p42 and p44 MAPK kinase inhibitor. Thus, the proteasome plays an important role in both inclusion body formation and dopaminergic neuronal death but these processes form opposite sides on the proteasome regulation in this model.
引用
收藏
页码:10710 / 10719
页数:10
相关论文
共 54 条
[1]   Degradation of α-synuclein by proteasome [J].
Bennett, MC ;
Bishop, JF ;
Leng, Y ;
Chock, PB ;
Chase, TN ;
Mouradian, MM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (48) :33855-33858
[2]   Chronic systemic pesticide exposure reproduces features of Parkinson's disease [J].
Betarbet, R ;
Sherer, TB ;
MacKenzie, G ;
Garcia-Osuna, M ;
Panov, AV ;
Greenamyre, JT .
NATURE NEUROSCIENCE, 2000, 3 (12) :1301-1306
[3]  
Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO
[4]  
2-0
[5]   A PRIMATE MODEL OF PARKINSONISM - SELECTIVE DESTRUCTION OF DOPAMINERGIC-NEURONS IN THE PARS COMPACTA OF THE SUBSTANTIA NIGRA BY N-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE [J].
BURNS, RS ;
CHIUEH, CC ;
MARKEY, SP ;
EBERT, MH ;
JACOBOWITZ, DM ;
KOPIN, IJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (14) :4546-4550
[6]   Proteasome involvement and accumulation of ubiquitinated proteins in cerebellar granule neurons undergoing apoptosis [J].
Canu, N ;
Barbato, C ;
Ciotti, MT ;
Serafino, A ;
Dus, L ;
Calissano, P .
JOURNAL OF NEUROSCIENCE, 2000, 20 (02) :589-599
[7]   Inhibition of proteasome function induces programmes cell death in proliferating endothelial cells [J].
Drexler, HCA ;
Risau, W ;
Konerding, MA .
FASEB JOURNAL, 2000, 14 (01) :65-77
[8]   Lewy bodies and parkinsonism in families with parkin mutations [J].
Farrer, M ;
Chan, P ;
Chen, R ;
Tan, L ;
Lincoln, S ;
Hernandez, D ;
Forno, L ;
Gwinn-Hardy, K ;
Petrucelli, L ;
Hussey, J ;
Singleton, A ;
Tanner, C ;
Hardy, J ;
Langston, JW .
ANNALS OF NEUROLOGY, 2001, 50 (03) :293-300
[9]   Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies [J].
Ferrer, I ;
Blanco, R ;
Carmona, M ;
Puig, B ;
Barrachina, M ;
Gömez, C ;
Ambrosio, S .
JOURNAL OF NEURAL TRANSMISSION, 2001, 108 (12) :1383-1396
[10]   Brain proteasomal function in sporadic Parkinson's disease and related disorders [J].
Furukawa, Y ;
Vigouroux, S ;
Wong, H ;
Guttman, M ;
Rajput, AH ;
Ang, L ;
Briand, M ;
Kish, SJ ;
Briand, Y .
ANNALS OF NEUROLOGY, 2002, 51 (06) :779-782